Expression of MYC gene in multiple myeloma with 1q21 amplification treated with bortezomib-based regimen and its clinical significance

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046294

Enrollment

Unknown

Registered

2021-05-12

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

According to the abnormal status of MYC gene, it was divided into rearrangement group, mutation group and no abnormality group. :Nil

Eligibility

Sex/Gender

All

Age

14 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 14 to 75 years; 2. In line with the diagnostic criteria of MM in China Multiple Myeloma (MM) diagnosis and treatment guidelines (2020 edition); 3. Newly diagnosis of MM; 4. FISH detection was accompanied by 1q21 amplification.

Exclusion criteria

Exclusion criteria: 1. Women who were pregnant (positive urine/blood pregnancy test) or lactating; 2. With severe cardiopulmonary insufficiency not caused by this disease; 3. Patients with a second tumor; 4. As judged by the researchers, the patients had other unsuitable conditions for inclusion; 5. No tolerance to bortezomib side effects or severe adverse reactions during treatment.

Design outcomes

Primary

Measure	Time frame
Myc gene status;Treatment efficacy;	—

Countries

China

Contacts

Public ContactXu Fang

Mianyang Central Hospital

147377807@qq.com+86 13778138821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026